Breaking News

Espero Pharma and Armetheon Merge

Creates a premier cardiovascular focused biopharmaceutical company

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Espero Pharmaceuticals, a privately held, commercial-stage cardiovascular pharmaceutical company, and Armetheon, a privately held, late-clinical stage pharmaceutical company developing novel drugs addressing major unmet needs in cardiovascular diseases, today announced their plans to merge. Upon completion of the merger, which is expected to occur in the second quarter of 2017, the combined company will be named Espero BioPharma, Inc. The merger will create a premier cardiovascular biopharmac...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters